Background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine by World Health Organisation SAGE Working Group on COVID-19 Vaccine
 
 
   
 Background document on the Janssen 




Background document to the WHO Interim 
recommendations for use of Ad26.COV2.S 
(COVID-19) vaccine 
17 March 2021 
  







Background ......................................................................................................................................................................... 3 
Context ................................................................................................................................................................................ 3 
Characteristics of Ad26.COV2.S (COVID-19) vaccine ...................................................................................................... 3 
Composition ................................................................................................................................................................... 3 
Dosing regimen .............................................................................................................................................................. 4 
Stability and shelf-life .................................................................................................................................................... 4 
Drug product description ................................................................................................................................................ 4 
Container ........................................................................................................................................................................ 4 
Preclinical studies ................................................................................................................................................................ 4 
Nonclinical immunogenicity and efficacy ...................................................................................................................... 4 
Biodistribution ................................................................................................................................................................ 4 
Toxicology ...................................................................................................................................................................... 4 
Developmental and reproductive toxicity ....................................................................................................................... 5 
Clinical studies .................................................................................................................................................................... 5 
Immunogenicity studies in humans ................................................................................................................................ 5 
Efficacy studies .............................................................................................................................................................. 5 
Efficacy against COVID-19 ....................................................................................................................................... 8 
Efficacy against severe COVID-19 (WHO clinical progression scale ≥ 6) ............................................................... 8 
Efficacy against COVID-19 hospitalization .............................................................................................................. 9 
Efficacy against deaths related to COVID-19 ............................................................................................................ 9 
Vaccine impact on symptom severity ........................................................................................................................ 9 
Efficacy in persons with previous SARS-CoV-2 infection (based on seropositivity at baseline) .............................. 9 
Efficacy against asymptomatic infections .................................................................................................................. 9 
Onset of efficacy after a single dose .......................................................................................................................... 9 
Efficacy against new variants of concern................................................................................................................... 9 
Summary of all vaccine efficacy results .................................................................................................................. 10 
Safety ............................................................................................................................................................................ 12 
Special considerations .................................................................................................................................................. 14 
References ......................................................................................................................................................................... 16 
Annexes ............................................................................................................................................................................. 18 
Annex 1. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in adults ........................................ 19 
Annex 2. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in adults ............................................ 20 
Annex 3. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in older adults ............................... 21 
Annex 4. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in older adults ................................... 22 
Annex 5. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in individuals with underlying 
conditions....................................................................................................................................................... 23 
Annex 6. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in individuals with underlying 
conditions....................................................................................................................................................... 24 
Annex 7. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in adults .................. 25 
Annex 8. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in older adults ......... 35 
Annex 9. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in individuals with 
comorbidities ................................................................................................................................................. 44 
 




This background document was prepared by the Strategic Advisory Group of Experts (SAGE) on Immunization 
Working Group on COVID-19 Vaccines to inform the discussions of SAGE at its 15 March 2021 meeting, which 
resulted in the issuance of the WHO interim recommendations for use of the Ad26.COV2.S (COVID-19) vaccine. 
Both the recommendations and the background document are available on the SAGE COVID-19 webpage: 
https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials.  
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries 
of the reported interests can be found on the SAGE meeting webpage and SAGE Covid-19 Working Group webpage.  
Context 
The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike 
protein and is based on the Ad26 vector platform. The adenoviruses are a group of viruses that cause infections in the 
respiratory and gastrointestinal tracts; the adenovirus vector used in the experimental vaccine has been modified, so that 
it can no longer replicate in humans and cause illness. In developing the vaccine, Janssen employed the same vector used 
in the first dose of its prime–boost vaccine regimen against Ebola virus disease (Ad26 ZEBOV and MVN-BN-Filo). As 
of 31 December 2020, Ad26-based vaccines have been used to vaccinate 193 831 participants in clinical studies and 
vaccination programmes. These more than 193 000 participants included people from different age groups (elderly, adults, 
children and infants), individuals positive for human immunodeficiency virus (HIV), and pregnant and breastfeeding 
women, and the data show a favourable safety profile. Ad26-based vaccines elicit strong humoral immune responses with 
both neutralizing activity and non-neutralizing antibody functionalities, and cellular immune responses involving both 
CD8+ T cells and CD4+ T-cells, the latter with a predominantly Th1 phenotype, irrespective of the transgene encoded 
immunogens (1-4). Overall, these vaccines have been shown to have an acceptable clinical safety profile to date.  
Data taken into consideration are those included in the US Food and Drug Administration Vaccines and Related 
Biological Products Advisory Committee (VRBPAC) meeting documentation, available under the following links: 
www.fda.gov/media/146217/download and www.fda.gov/media/146218/download.  
Characteristics of Ad26.COV2.S (COVID-19) vaccine 
The Janssen COVID-19 Vaccine is a replication-incompetent adenovirus type 26 (Ad26)-vectored monovalent vaccine 
encoding the SARS-CoV-2 spike (S) protein from the Wuhan-Hu-1 isolate (GenBank accession number MN908947), 
stabilized in its prefusion conformation. The vector cannot replicate in human cells because the E1 gene was deleted from 
the genome. To manufacture vaccines that are based on replication incompetent adenoviral vectors, a specific cell line is 
used that complements for the missing E1 gene. This cell line is derived from a single human primary cell, obtained in 
1985 from fetal retina tissue (at 18 weeks of gestation adhering to the Dutch laws that were in effect). The cell line was 
established by transformation of the primary cells using the Adenovirus E1 gene which resulted in a cell line that 
constitutively expresses E1, and that is thus able to complement the adenoviral vector that misses E1, allowing the vector 
to replicate during the manufacturing process. Another consequence of the E1 transformation is that the cell line can be 
propagated indefinitely and as a result, there is no need to go back to the primary cells in any part of the scientific discovery 
or manufacturing process. The Ad26 vector expressing the S protein is grown in PER.C6G TetR cell line, in media 
containing amino acids and no animal-derived proteins. After propagation, the vaccine is processed through several 
purification steps, formulated with inactive ingredients and filled into vials. 
Composition 
One dose (0.5 ml) contains 5 x 1010 AD26.COV2.S viral particles (vp).  
The vaccine also contains the following inactive ingredients: citric acid monohydrate, trisodium citrate dihydrate, ethanol, 
2-hydroxypropyl-beta-cyclodextrin (HBCD), polysorbate 80, sodium chloride, sodium hydroxide, and hydrochloric acid.  
The vaccine does not contain preservatives.  




Ad26.COV2.S is administered as a single intramuscular injection (0.5 ml dose).  
Stability and shelf-life  
The vaccine is provided to country at -20°C with a shelf life of 24 months in a multi-dose vial containing 5 doses (0.5ml 
each). The vaccine could be stored at 2°C to 8°C for 3 months. Once thawed the vaccine should not be re-frozen. The 
vials should be protected from light. After the first dose has been withdrawn, the vial should be held between at 2°C to 
8°C for up to 6 hours in compliance with WHO Multidose open vial policy. Any remaining dose of opened vial must be 
discarded after 6 hours or at the end of the immunization session, whichever comes first. 
Drug product description 
The Janssen Ad26.COV2.S vaccine is a colourless to slightly yellow, clear to very opalescent sterile suspension for 
intramuscular injection.  
Container 
Each multidose vial contains a fill volume of 3.1 ml to allow for an extractable volume of 2.5 ml, as 5 extractions of 0.5 
ml.  
The vaccine does not require reconstitution.  
Preclinical studies 
Nonclinical immunogenicity and efficacy 
A single dose of Ad26.COV2.S induced a rapid onset of SARS-CoV-2 neutralizing and S protein-binding antibodies in 
all species tested (mice, rabbits, Syrian hamsters, and nonhuman primates). Cellular immunity was seen in mice and 
nonhuman primates, with CD4+ T cells, predominantly of the Th1 phenotype, and IgG-producing CD8+ T cells.  
In Syrian hamsters, a single dose of Ad26.COV2.S significantly reduced viral load in the lungs after SARS-CoV-2 
challenge, in comparison with mock-vaccinated and challenged controls. In nonhuman primates, undetectable viral load 
in the nose was observed in the majority, and undetectable viral load in the lungs was recorded for all animals. (5, 6).  
Duration of protection: Almost all vaccinated macaques had undetectable lung viral load after challenge 6 months after 
vaccination (7). 
Vaccine enhanced respiratory disease (VAERD): In all Syrian hamsters and nonhuman primates vaccinated with 
Ad26.COV.2S and subsequently challenged with SARS-CoV-2, no increased lung histopathology, infectious viral load, 
or clinical signs were observed, indicating the absence of any signs of VAERD (8).  
Biodistribution 
The biodistribution profile of the Ad26 vector platform was evaluated in New Zealand White rabbits. The Ad26 vector 
did not widely distribute following intramuscular administration. Vector DNA was detected at the site of injection, in 
draining lymph nodes, and (to a lesser extent) in the spleen. The Ad26 vector showed clearance from these tissues.  
Toxicology 
In a repeat-dose toxicity and local tolerance study in New Zealand White rabbits, IM administration of Ad26.COV2.S at 
1×1011 vp/dose on three occasions, with a 14-day interval period, was well tolerated. There were no adverse vaccine-
related effects noted. 
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Developmental and reproductive toxicity 
In a combined embryo-fetal and pre- and postnatal development toxicity study, 3 doses of Ad26.COV2.S at 
1x1011 vp/dose were administered at 1x1011 intramuscularly to female New Zealand White rabbits during the premating 
and gestation period. There was no adverse effect of Ad26.COV2.S on fertility, or embryo-fetal and postnatal development.  
Clinical studies 
The pivotal safety, efficacy and immunogenicity data informing registration of the vaccine are derived from five ongoing 
studies: 
• COV1001: a phase 1/2 trial in 1045 adults (1-dose and 2-dose regimens, with booster in 1 cohort); 
• COV1002: a phase 1 safety and immunogenicity study in 250 adults (2-dose regimen); 
• COV2001: a phase 1a safety and immunogenicity study involving 550 adults and 660 adolescents (1-dose and 
2-dose regimens) (enrolment of adolescents has not yet started); 
• COV3001: a phase 3 efficacy and safety trial in 40 000 adults (1-dose regimen) (enrolment complete); 
• COV3009: a phase 3 efficacy and safety trial in 30 000 adults (2-dose regimen) (enrolment ongoing); 
The primary analysis of vaccine efficacy from the study COV3001 is used here as the main source of data.  
Studies in other populations (i.e, pregnant women, children with and without comorbidities) are planned in the near 
future.  
Immunogenicity studies in humans 
Study COV1001 (healthy adults ages 18 to 55 in the United States and Belgium): A single dose of Ad26.COV2.S elicited 
a SARS-CoV-2 neutralizing antibody (wtVNA) and SARS-CoV-2 spike binding antibody response that was detected by 
Day 15 and is increased by Day 57. Ad26.COV2.S was able to elicit cellular responses in participants with a Th-1 
phenotype. Ad26.COV2.S, given as a single dose was found to have an acceptable safety and reactogenicity profile in 
adults aged 18 years and above and did not raise safety concerns in any of the assessed populations. 
Study COV1002 (healthy adults ages 20-55, and ≥65 years of age and above in good health, in Japan): Two doses were 
given at a 56-day interval. Neutralizing antibody responses by day 29 post-vaccination with a single dose were similar to 
Study COV1001.  
Study COV2001 is an ongoing, randomized, double-blind, placebo-controlled Phase 2a study, conducted in Germany, 
Spain, and the Netherlands in healthy adults ≥18 to ≤55 years of age, and adults in good or stable health ≥65 years of 
age. The primary objectives of this study are to assess safety and reactogenicity and humoral immune response of 
Ad26.COV2.S across different doses and intervals (for 2-dose regimens). Recently, adolescents aged 12 to 17 years were 
included. 
Across Phase 1 and 2 studies at Day 29, a SARS-CoV-2 neutralizing antibody response was observed in at least 88% of 
participants aged 18 to 55 years and at least 93% of participants aged 65 and above. Neutralizing and binding antibody 
responses continued to increase from Day 29 to Day 57 and were maintained to at least Day 85, with very high responder 
rates across the age groups. A single dose of Ad26.COV2.S elicited SARS-CoV-2 CD4+ and CD8+ T cell responses by 
Day 15 and up to Day 29 in the majority of adult participants aged 18 to 55, and aged 65 and above.  
Efficacy studies 
Study COV3001, which used a 1-dose regimen, provides the primary analyses for this background paper. Study COV3001 is 
an ongoing, multicentre, randomized, double-blind, placebo-controlled phase 3 study to assess the efficacy, safety and 
immunogenicity of a single dose (5×1010 vp) of Ad26.COV2.S for the prevention of COVID-19 in adults aged 18 years and 
older. The study is being conducted in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the USA. A total of 
44 325 participants were randomized, of whom 43 783 were given either Ad26.COV2.S or placebo. The study was well 
balanced among subgroups with regard to age, comorbidities, sex, region, race, and ethnicity. The study was initiated at sites 
expected to experience high incidence of COVID-19 on 21 September 2020. The time of study enrollment coincided with a 
marked increase of incidence of COVID-19 and the emergence of new SARS-CoV-2 variants, which were emerging in some 
of the countries where study COV3001 was being conducted. Efficacy results were based on the primary analysis, which 
included 19 630 participants who received the vaccine and 19 691 participants who received placebo. 
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At the time of the primary analysis, 464 central laboratory-confirmed primary endpoint cases with an onset at least 14 
days after vaccination included in the per protocol analysis set, of which 259 cases occurred at least 28 days after 
vaccination. The primary analysis included centrally confirmed cases only. Because of the high in-study incidence of 
COVID-19 and the time needed for central laboratory confirmation of the local polymerase chain reaction (PCR) test, not 
all cases could be confirmed by the central laboratory at the time of the primary analysis. As a result, there were two data 
sets: a data set of centrally confirmed primary endpoint COVID-19 cases (464 after day 14, 259 after day 28) and a data 
set including all primary endpoint COVID-19 cases with a positive PCR from any source, regardless of central 
confirmation (682 after day 14, 437 after day 28). Vaccine efficacy (VE) estimates based on the two data sets differed by 
less than 1% and had similar confidence intervals (CIs). Among the cases that were centrally confirmed, a high 
concordance was observed (90.3%). For subgroup analyses, COVID-19 requiring medical intervention, and COVID-19-
related deaths, the data set including non-centrally confirmed cases was used to increase the robustness of the conclusions. 
The primary analysis included centrally confirmed cases only. 
The co-primary endpoints in study COV3001 were the first occurrence of PCR-confirmed COVID-19, including both 
moderate and severe/critical COVID-19 cases according to their case definitions, with onset at least 14 days or at least 28 
days after vaccination. All other efficacy endpoints were also evaluated in relation to cases that occurred at least 14 days 
or at least 28 days after vaccination. The primary efficacy analysis was performed after 50% of the participants had been 
followed for 8 weeks from the day of vaccination, on 22 January 2021, with 464 primary endpoint cases at least 14 days 
after vaccination and 259 primary endpoint cases at least 28 days after vaccination. Because of the limited number of mild 
COVID-19 cases, the co-primary endpoints capture almost all observed symptomatic COVID-19 cases. The total number 
of symptomatic cases (468 at least 14 days after vaccination and 261 at least 28 days after vaccination) was very similar 
to the total number of moderate and severe/critical COVID-19 cases. Participants will continue to be followed up for up 
to 24 months, for assessments of both safety and efficacy of the vaccine against COVID-19. Following emergency use 
authorization, Janssen proposes to change the study design, offering a single dose of Ad26.COV2.S to participants who 
initially received placebo, resulting in de facto unblinding of participants and investigators. 
  





Placebo (21 888) All participants 
(43 783) 
18–59 years, total 14 564 14 547 29 111 
Participants with at least 8 
weeks follow- up 62.8% 63.1% 63.0% 
Median follow-up after 
vaccination (days) 61.0 61.0 61.0 
18–59 years, no comorbidities 9332 9371 18 703 
Participants with at least 8 
weeks follow- up 70.0% 69.9% 70.0% 
Median follow-up after 
vaccination (days) 64.0 64.0 64.0 
18–59 years, with comorbidities 232 5176 10 408 
Participants with at least 8 
weeks follow- up 49.9% 50.8% 50.4% 
Median follow-up after 
vaccination (days) 56.0 57.0 57.0 
≥60 years, total 7331 7341 14672 
Participants with at least 8 
weeks follow- up 38.2% 37.8% 38.0% 
Median follow-up after 
vaccination (days) 52.0 52.0 52.0 
≥60 years, no comorbidities 3627 3595 7222 
Participants with at least 8 
weeks follow- up 47.6% 49.0% 48.3% 
Median follow-up after 
vaccination (days) 54.0 55.0 54.0 
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≥60 years, with comorbidities 3704 3746 7450 
Participants with at least 8 
weeks follow- up 29.0% 27.1% 28.0% 
Median follow-up after 
vaccination (days) 50.0 50.0 50.0 
Boxes 1 and 2 provide respectively the primary endpoint case definitions for moderate and severe/critical COVID-19 
cases used in the efficacy studies.  




1 The case definitions used were developed by Janssen and differ from WHO standard definitions of COVID-19 disease severity which 
can be found in: COVID-19 Clinical management: living guidance (https://www.who.int/publications/i/item/WHO-2019-nCoV-
clinical-2021-1, accessed 16 March 2021).  
The case definition for moderate COVID-19 was a positive SARS-CoV-2 reverse transcription (RT)-PCR 
or molecular test result from any available respiratory tract sample (e.g. nasal, throat, sputum, saliva) or other 
sample,  
and at any time during the course of observation,  
either: 
• any one of the following new or worsening signs or symptoms: 
o respiratory rate ≥20 breaths/minute, 
o abnormal saturation of oxygen (SpO2) but still >93% on room air at sea level, 
o clinical or radiological evidence of pneumonia, 
o radiological evidence of deep vein thrombosis, 
o shortness of breath or difficulty breathing 
or: 
• any two of the following new or worsening signs or symptoms: 
o fever (≥38.0°C or ≥100.4°F), 
o heart rate ≥90 beats/minute, 
o shaking chills or rigors, 
o sore throat, 
o cough, 
o malaise, as evidenced by loss of appetite, fatigue, physical weakness, and/or feeling 
unwell, 
o headache, 
o muscle pain (myalgia), 
o gastrointestinal symptoms (diarrhoea, vomiting, nausea, abdominal pain), 
o new or changing olfactory or taste disorders, 
o red or bruised-looking feet or toes. 
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Box 2: Case definition for severe/critical COVID-192 
 
 
Box 3 provides the list of secondary endpoints considered. 
 
Box 3: Secondary efficacy endpoints 
 
All cases meeting the severe/critical criteria were adjudicated by the Clinical Severity Adjudication Committee. 
Classification of a case as severe/critical by the Clinical Severity Adjudication Committee was considered definitive. 
Efficacy against COVID-19 
COV3001 demonstrated vaccine efficacy for both co-primary endpoints. A single dose of Ad26.COV2.S protected against 
moderate to severe/critical COVID-19 in adults ≥18 years of age, including adults ≥60 years of age, with an efficacy 
that was consistent across age groups but with some variability across countries (Table 2). Vaccine efficacy against first 
occurrence of moderate to severe/critical COVID-19, including non-centrally confirmed cases, was 66.9% (95% CI 59.0-
73.4), 14 days after vaccination, and 66.1% (55.0-74.8%) 28 days after vaccination. 
Efficacy against severe COVID-19 (WHO clinical progression scale ≥ 6) 
The vaccine was highly efficacious against severe/critical COVID-19. Efficacy was consistently high across age groups, 
regions, and countries. As a prespecified secondary endpoint, the vaccine also prevented COVID-19 requiring medical 
intervention (defined as hospitalization, ICU admission, mechanical ventilation, ECMO linked to objective measures, 
such as decreased oxygenation, X-ray or computerized tomography (CT) findings) and COVID-19-related deaths, with 
all hospitalizations and deaths after day 28 occurring in the placebo group. 
 
2 The case definitions used were developed by Janssen and differ from WHO standard definitions of COVID-19 disease severity which 
can be found in: COVID-19 Clinical management: living guidance (https://www.who.int/publications/i/item/WHO-2019-nCoV-
clinical-2021-1, accessed 16 March 2021).  
The case definition for severe/critical COVID-19 was an RT-PCR or molecular test result from samples 
described above and any one of the following at any time during the course of observation: 
 
• clinical signs at rest indicative of severe systemic illness (respiratory rate ≥30 breaths/minute, 
heart rate ≥125 beats/minute, oxygen saturation (SpO2) ≤93% on room air at sea level, or partial 
pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) <300 mmHg), 
• respiratory failure (defined as needing high-flow oxygen, non-invasive ventilation, 
mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)), 
• evidence of shock (defined as systolic blood pressure <90 mmHg, diastolic blood 
pressure <60 mmHg, or requiring vasopressors), 
• significant acute renal, hepatic, or neurological dysfunction, 
• admission to the intensive care unit (ICU), 
• death. 
 
Secondary efficacy endpoints included vaccine efficacy to prevent or vaccine impact on: 
• Severe/critical COVID-19 
• COVID-19 requiring medical intervention 
• COVID-19 related death 
• Any asymptomatic COVID-19 
• Asymptomatic COVID-19 as inferred through seroconversion 
• COVID-19 per the U.S. Food and Drug Administration harmonized COVID-19 case definition 
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The case splits for severe/critical COVID-19 in the vaccine and placebo groups virtually eliminate the risk of VAED, 
consistent with the Th1-skewed immunological response. 
 
Efficacy against COVID-19 hospitalization 
In the per protocol analysis set, 14 days or more after vaccination, there were 2 COVID-19-related hospitalizations in the 
vaccinated group and 29 in the placebo group (VE 93.1%, 95%CI 72.74–99.20%).  
In the per-protocol analysis set, 28 days or more after vaccination, there were no COVID-19-related hospitalizations in 
the vaccinated group and 16 in the placebo group (VE 100%, 95%CI 74.26–100.00%).  
Efficacy against deaths related to COVID-19 
There were no COVID-19-related deaths in the Ad26.COV2.S group and 6 COVID-19-related deaths in the placebo group.  
Vaccine impact on symptom severity 
A post-hoc analysis found that the participants with moderate COVID-19 who received Ad26.COV2.S most frequently 
reported 4 to 6 symptoms, while participants in the placebo group reported 7 to 9 symptoms.  
Efficacy in persons with previous SARS-CoV-2 infection (based on seropositivity at baseline) 
Only 7 symptomatic cases of COVID-19 were observed in participants who were SARS-CoV-2 seropositive at baseline, 
so it is not possible to provide meaningful comments on the VE in these participants. 
Efficacy against asymptomatic infections 
Preliminary data, based on serology results on day 71, suggest a vaccine effect against asymptomatic infection, based on 
the data cut-off for the primary analysis of 22 January 2021 (updated analysis submitted to FDA on 12 February 2021). 
Among 2650 individuals for whom day 71 results were available, 50 in the placebo group had evidence of an 
asymptomatic or undetected infection versus 18 in the Ad26.COV2.S group (VE 65.5%, 95%CI 39.91–81.08%). A 
sensitivity analysis, which removed all participants who had had symptoms at any time since screening prior to the SARS-
CoV-2 N IgG positive result, found 10 and 37 seroconversions in the vaccinated and placebo group, respectively (VE 
74.2%, 95%CI 47.13–88.57%).  
Onset of efficacy after a single dose 
The onset of VE against moderate to severe/critical COVID-19 was observed at 14 days after vaccination; efficacy 
persisted for the duration of follow-up (median 58 days). The onset of efficacy against severe/critical COVID-19 was 
observed at 7 days after vaccination, with a clear trend of increasing VE that persisted for the duration of follow-up 
(median 58 days). This rise in VE is consistent with available immunogenicity results from phase 1/2a studies. Participants 
with moderate COVID-19 in the Ad26.COV2.S group experienced fewer and less severe symptoms than those in the 
placebo group.  
Efficacy against new variants of concern 
In the USA, VE against moderate to severe/critical COVID-19 and against severe/critical COVID-19 was consistent with 
the global VE findings. In South Africa, where the 20H/501Y.V2 variant (B.1.351 lineage) was the predominant strain 
(96.3% of sequenced cases thus far), high efficacy was observed against severe/critical COVID-19 (81.7%, 95%CI 46.2–
95.4% at least 28 days after vaccination) and robust VE was observed for moderate to severe/critical COVID-19 (64.0%, 
95%CI 41.2–78.7% at least 28 days after vaccination). In Brazil, where a variant from the P.2 lineage was the predominant 
strain (70.7% of sequenced cases thus far), VE estimates were similar to the USA and South Africa. No differences were 
observed in S-specific binding antibody levels and responder rates induced by Ad26.COV2.S between participants from 
Brazil, South Africa, and the USA. 
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Table 2. Vaccine efficacy >day 28 against COVID-19 disease according to severity endpoint in the United States, 
Brazil and South Africa 
Country  
(% Variant) Disease severity endpoint No. of events/ N 
VE% (95% CI) 
>Day 28 
  Vaccine 
group 










32 / 8 958 112 / 8 835 72.0% (58.2–81.7) 
Severe/Critical 1 / 8 958 7 / 8 835 85.9% (-9.4–99.7) 
Brazil 




24 / 3 354 74 / 3 312 68.1% (48.8–80.7) 






23 / 2 449 64 / 2 463 64.0% (41.2–78.7) 
Severe/Critical 4 / 2 449 22 / 2 463 81.7% (46.2–95.4) 
Summary of all vaccine efficacy results 
Tables 3 summarizes the vaccine efficacy results.  
 
Table 3. Vaccine efficacy against first occurrence of moderate to severe/critical COVID-19, including non-centrally 
confirmed cases 








No. of cases/N 
(Total person-years) VE% (95% CI) 
Vaccine group Placebo group  Vaccine group 
Placebo 
group  



































Age group (years) 

































3 If fewer than 6 cases were observed for an endpoint, the VE is not shown 
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(10.5–76.3%) 10/1380 13/1378 23.0% 
Baseline SARS-CoV-2 status 

































This section draws on the safety findings of the phase 3 COV3001 study. Ad26.COV2.S demonstrated an acceptable 
safety and reactogenicity profile in adults ≥18 years of age, and in adults ≥60 years of age, including those with 
comorbidities associated with an increased risk of progressing to severe/critical COVID-19. In line with other Ad26-based 
vaccines, hypersensitivity reactions following immunization with Ad26.COV2.S were rare and usually nonserious. In 
COV3001, no cases were observed that met the Brighton Collaboration criteria for anaphylaxis. However, in an open-
label trial in South Africa, one case of anaphylaxis occurred which met the Brighton Collaboration criteria. 77 events of 
hypersensitivity were reported in COV 3001. 
In general, lower reactogenicity was observed in older adults than in younger adults. Otherwise, no clinically relevant 
difference in the reactogenicity profile of Ad26.COV2.S was observed by sex, race, ethnicity, geography, comorbidity, 
or SARS-CoV-2 or HIV serostatus at baseline (although numbers in some of these subgroups were too low to allow firm 
conclusions to be drawn). Reactogenicity was transient and most solicited adverse events (AEs) resolved in one to two 
days after vaccination. No grade 4 solicited local AEs were reported. 
Among the 43 783 participants who received a single dose of Ad26.COV2.S at 5×1010 vp, the median follow-up after 
vaccination was 58 days, and 23 903 (54.6%) participants had at least 2 months (8 weeks) of follow-up at the time of the 
primary analysis. In the safety subset of 6736 participants, 99.9% of the participants in each group completed the post-
vaccination follow-up period (days 1–29). A longer safety follow-up of 2 months or more is available for more than 
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23 000 participants in the full analysis set (FAS) (11 948 participants in the Ad26.COV2.S group and 11 955 in the placebo 
group). 
The safety subset data included both solicited AEs collected from the day of vaccination until 7 days afterwards and 
unsolicited AEs collected from the day of vaccination until 28 day afterwards. Data on medically-attended adverse events 
(MAAEs), serious adverse events (SAEs) and deaths were collected from all 43 783 participants who received a study 
vaccination (21 895 in the Ad26.COV2.S 5x1010 vp group and 21 888 in the placebo group) and will continue to be 
collected until end of the study. 
Frequencies of solicited and unsolicited AEs 
In general, solicited AEs (both local and systemic) occurred at a higher frequency in participants in the Ad26.COV2.S 
group than in the placebo group. Regardless of the group, most solicited AEs were grade 1 or 2 in severity and were 
transient in nature. No grade 4 (serious) solicited AEs were reported during the study. The most frequently reported grade 
3 solicited local AE was pain at the vaccination site, which was reported by 11 (0.3%) participants in the Ad26.COV2.S 
group. 
Grade 3 solicited systemic AEs were reported by fewer than 2.0% of participants in the Ad26.COV2.S group. Pyrexia of 
any grade was reported by 302 participants (9.0%) and grade 3 pyrexia was reported by 8 (0.2%) participants in the 
Ad26.COV2.S group, of which the majority occurred in the younger age group (below 35 years of age). A total of 5.2% 
of participants in the Ad26.COV2.S group used analgesics or antipyretics up to 7 days after vaccination. 
Overall, there was no apparent difference in unsolicited AEs reported in the Ad26.COV2.S group and the placebo group. 
The most frequently reported unsolicited AEs by preferred term (PT) (1.0% of participants in the Ad26.COV2.S group) 
were headache, fatigue, myalgia, and vaccination site pain, which were also recorded as solicited AEs. The most 
frequently reported unsolicited AEs (1.0% of participants in the Ad26.COV2.S group), not recorded as solicited AEs were 
chills, arthralgia, cough, nasal congestion, and diarrhoea. Most were of mild or moderate severity and most were 
considered by the investigator not to be related to the study vaccine. Other unsolicited AEs were reported in <1.0% of 
participants in the Ad26.COV2.S group. 
The frequency of unsolicited AEs that were considered by the investigator to be related to the study vaccine was higher 
in participants in the Ad26.COV2.S group (242/440, 55%) than in the placebo group (154/407, 37.8%). 
There were no notable patterns or numerical imbalances between the vaccine and placebo group for specific categories of 
AEs of interest (including neurological, neuroinflammatory and cardiovascular events) that would suggest a causal 
relationship to the vaccine. There were numerically more cases of tinnitus, convulsions/seizures, and pulmonary 
embolism/deep vein thrombosis in the Ad26.COV2.S group. However, in the majority of the cases the participants had 
one or more underlying medical conditions that were known risk factors for the event in question, and these events were 
most likely not causally related to the vaccine.  
Solicited and unsolicited adverse events are summarized in Tables 4 and 5.  
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Any local reaction 1218 (59.8%) 413 (20.2%) 467 (35.4%) 244 (18.3%) 
Grade 3 18 (0.9%) 4 (0.2%) 5 (0.4%) 2 (0.2%) 
Pain 1193 (58.6%) 357 (17.4%) 439 (33.3%) 207 (15.6%) 
Grade 3a 8 (0.4%) 0 3 (0.2%) 2 (0.2%) 
Erythema 184 (9.0%) 89 (4.3%) 61 (4.6%) 42 (3.2%) 
Grade 3b 6 (0.3%) 2 (0.1%) 1 (0.1%) 0 
Swelling 142 (7.0%) 32 (1.6%) 36 (2.7%) 21 (1.6%) 
Grade 3b 5 (0.2%) 2 (0.1%) 2 (0.2%) 0 
a Grade 3 pain is pain requiring use of prescribed pain reliever or that prevents daily activity. 
b Grade 3: >100 mm. 
Note: No grade 4 solicited local adverse reactions were reported. 
 
Table 5. Unsolicited adverse events occurring in ≥1% of vaccine group participants within 28 days following 











Any grade ≥Grade 3 Any grade ≥Grade 3 
General disorders  211 (6.3%) 5 (0.1%) 134 (4.0%) 2 (0.1%) 
Chills 67 (2.0%) 1 (<0.1%) 19 (0.6%) 0 
Fatigue 64 (1.9%) 1 (<0.1%) 77 (2.3%) 1 (<0.1%) 
Vaccination site pain 42 (1.3%) 1 (<0.1%) 22 (0.7%) 0 
Musculoskeletal and 
connective tissue disorders 
103 (3.1%) 3 (0.1%) 89 (2.6%) 4 (0.1%) 
Myalgia 49 (1.5%) 0 58 (1.7%) 2 (0.1%) 
Arthralgia 35 (1.0%) 1 (<0.1%) 24 (0.7%) 2 (0.1%) 
Nervous system disorders 98 (2.9%) 3 (0.1%) 108 (3.2%) 5 (0.1%) 
Headache 72 (2.1%) 1 (<0.1%) 82 (2.4%) 1 (<0.1%) 
Respiratory, thoracic and 
mediastinal disorders 
93 (2.8%) 3 (0.1%) 88 (2.6%) 4 (0.1%) 
Nasal congestion 40 (1.2%) 1 (<0.1%) 38 (1.1%) 2 (0.1%) 
Cough 33 (1.0%) 1 (<0.1%) 33 (1.0%) 0 
Gastrointestinal disorders 87 (2.6%) 2 (0.1%) 90 (2.7%) 2 (0.1%) 
Diarrhoea 33 (1.0%) 2 (0.1%) 35 (1.0%) 0 




Up to the cutoff date of 31 December 2020, 8 pregnancy were reported in this study. In 3 cases, vaccine exposure occurred 
within 3 months preceding the date of conception with pregnancy outcomes reported as continuing/ongoing or 
unknown/not reported. In 5 cases, vaccine exposure occurred during the first trimester of pregnancy with pregnancy 
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outcomes reported as continuing/ongoing (3), elective abortion (1), or spontaneous abortion (1; assessed as not related to 
blinded vaccine/placebo). No additional pregnancies were reported between 31 December 2020 and 22 January 2021.  
A combined developmental and perinatal/postnatal reproductive toxicity study in rabbits concluded that Ad26.COV.2 
given prior to mating and during gestation periods at double the human dose did not have any adverse effects on female 
reproduction, fetal/embryonal development or postnatal development.  
A pregnancy substudy and pregnancy registry are planned. 
Ad26 vector platform (non-COVID-19) in pregnancy:  
There is some experience with use of the Ad26 vector platform in pregnancy (9).  
Janssen has prepared an ad hoc safety report (21 Jan 2021) on the pregnancy experience across the entire Ad-based vaccine 
program. Included in this report is the experience obtained from EBL3008 (also known as DRC-EB-001) as the single 
largest contributor to the report. EBL3008 deliberately allowed pregnant women to be included in the study, whereas for 
the other Ad-based studies, inclusion of pregnant women was not permitted. EBL3008 was open-label study sponsored 
by the London School of Hygiene and Tropical Medicine and thus there is no control comparison group to establish a 
country-specific background rate of events.  
With that understanding, the summary data includes a safety review of adenovirus type 26 (Ad26) vectored vaccines 
exposure during pregnancy from ongoing and completed clinical trials as well as post-market mass vaccination campaign 
(47 studies) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) vaccine, Ebola vaccine, 
Human Immunodeficiency Virus (HIV) vaccine, Filovirus vaccine, Human Papilloma Virus (HPV) vaccine, Respiratory 
Syncytial Virus (RSV) vaccine, and Zika vaccine. Of these 47 studies, pregnancy cases were reported in 22 studies, 4 of 
which are still blinded. 
Cumulative searches through 31 December 2020 were performed in the Global Medical Safety (GMS) global safety 
database for all the pregnancy cases reported from completed and ongoing trials for Ad26 vectored vaccines which 
included COVID-19 vaccine, Ebola vaccine, HIV vaccine, Filovirus vaccine, HPV vaccine, RSV vaccine, and Zika 
vaccine. 
The search of the GMS global safety database retrieved 2 061 cases involving exposure during pregnancy in participants 
who received an Ad26 vectored vaccine or control. Data from 430 cases are not presented below as these cases (and 
outcomes) were reported either more than 3 months before vaccine exposure or 9 months after vaccine exposure, or with 
no history of exposure to vaccine or male partner exposure. 
The remaining 1 631 cases reported unique pregnancies and were included for further review. Of these 1 631 pregnancies, 
1 522 reported exposure to Ebola vaccine or placebo in the Ebola program, 101 reported exposure to HIV vaccine or 
placebo in the HIV program and 8 reported exposure to COVID-19 vaccine or placebo in COVID-19 program. None of 
the cases reported exposure to HPV vaccine, RSV vaccine, Filovirus vaccine, or Zika vaccine. Of the 1 522 pregnancies 
reported from the Ebola vaccine trials with reported exposure to Ad26.ZEBOV vaccine, most cases were reported in 
VAC52150EBL3008 with 1 062 reported pregnancies. 
Of the 1 631 unique pregnancies, outcome was reported with 939 final pregnancy outcomes: healthy baby for 781 and 
various other outcomes for 158 pregnancies including 102 spontaneous abortions, 19 stillbirths, 9 elective abortions, 7 
intrauterine deaths, 6 induced abortions, 5 premature babies/labours, 3 congenital malformations, 3 ectopic pregnancies, 
2 abortion incompletes, 1 abortion, and 1 termination; there are also 243 ongoing pregnancies, and unknown/not reported 
for 449.
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Of these 1 631 pregnancies, caesarean section delivery was reported as delivery method in 193 pregnancies and 
61 reported normal delivery. 
Of the 1 522 pregnancies reported from the Ebola vaccine trials with reported exposure to Ad26.ZEBOV vaccine, 
most cases were reported in VAC52150EBL3008 with 1 062 reported pregnancies. 
Spontaneous abortion was reported in 5.8% (88/1 522) of pregnancies, whereas all other types of abortions (i.e., 
induced abortion [6], elective abortion [5], abortion, abortion incomplete and incomplete abortion [each reported 
once] were reported in 0.9% (14/1 522) of pregnancies. Congenital malformations reported in 3 cases were lingula 
frenulum, cleft lip and evisceration on exomphalos, none of which were considered related to the study vaccine. 
In addition, none of the reported adverse pregnancy outcomes and SAEs was considered related to the study 
vaccine. 
Of the 101 pregnancies reported from the HIV vaccine trials with exposure to Ad26.Mos4.HIV candidate vaccine, 
the most frequently reported study protocol was VAC89220HPX2008 with 90 reported pregnancies. In this study, 
only women are recruited. Spontaneous abortion was reported in 12.9% (13/101) and elective abortion in 3% 
(3/101) pregnancies. None of the pregnancies reported any congenital malformations. None of the reported 
adverse pregnancy outcomes and SAEs were considered related to the study vaccine. 
All 8 pregnancies reported from COVID-19 vaccine trials were from protocol VAC31518COV3001. There was 
1 case each for spontaneous abortion and elective abortion 12.5% (1/8). None of the pregnancies reported any 
congenital malformations. None of the reported adverse pregnancy outcomes and SAEs were considered related 
to the study vaccine. 
The reported spontaneous abortion rates are within the expected abortion rates during pregnancy which could 
range anywhere from 10% to 30%. (10) 
Overall, the review of the available data is not suggestive of a pregnancy related safety concern. 
 
Breastfeeding 
It is unknown whether the vaccine is excreted in human milk. 
Pediatric population  
No data are available in subjects under 18 years of age.  
Immunosuppression  
No data are currently available from immunocompromised subjects, including those receiving 
immunosuppressant therapy. The efficacy of the vaccine may be lower in immunosuppressed individuals.  
Safety related to vaccine interactions  
No data are available on use of the vaccine with concomitant vaccines, including influenza vaccines. Licensed 
seasonal influenza and pneumococcal vaccinations were permitted at least 7 days before or after the study vaccine. 
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Annexes 1–6 contain tables that summarize the grading of recommendations, assessment, development and 
evaluations (GRADE). Annexes 7–9 contain the SAGE evidence-to-recommendation framework tables (ETR 
tables). The ETR tables are based on the DECIDE Work Package 5: Strategies for communicating evidence to 
inform decisions about health system and public health interventions. Evidence to a recommendation (for use by 
a guideline panel) (www.decide-collaboration.eu/, accessed 11 January 2021). 
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Annex 1. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in adults  
 
Population : Adults (18–59 years) 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison: Placebo/active control 
Outcome  : Moderate to severe/critical COVID-19 (PCR-confirmed) 
What is the efficacy of a single dose of Janssen AD26.COV2.S vaccine compared with placebo/active control in preventing 
moderate to severe/critical PCR-confirmed COVID-19 in adults (18–59 years)? 
    Rating Adjustment to rating 
   


















Limitation in study 
designa Not serious
b 0 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  













Statement on quality of evidence 
Evidence supports a high level of confidence 
that the true effect lies close to the estimate of 
the effect on the health outcome (level 4, or 
⊕⊕⊕⊕). 
Conclusion 
We are very confident that a single dose of Janssen 
AD26.COV2.S vaccine is efficacious in preventing 
moderate to severe/critical PCR-confirmed COVID-
19 in adults (18–59 years). 
 
References 
1. FDA Briefing Document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. 
(https://www.fda.gov/media/146217/download, accessed 25 February 2021). 
2. Sadoff J, Le GM, Shukarev G, Heerwegh D, Truyers C, de Groot AM et al. Interim results of a phase 1-2a 
trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021; Jan 13. 
  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Data on long-term protection emerging from the ongoing phase 3 clinical trial remain limited, as trial data have so far been 
reported only for a follow-up of approximately 2 months. This was considered as not constituting a limitation that would lead 
to downgrading of the evidence. SAGE will continue to review any emerging data and adjust its quality assessment as required. 
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Annex 2. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in adults 
 
Population :  Adults (18–59 years) 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison: Placebo/active control  
Outcome     : Serious adverse events following immunization 
What is the risk of serious adverse events following Janssen AD26.COV2.S vaccination compared with placebo/active control 
in adults (18–59 years)? 
    Rating Adjustment to rating 
   











No. of studies/starting rating 






Limitation in study 
designa Serious
b -1 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  













Statement on quality of evidence 
Evidence supports a moderate level of 
confidence that the true effect lies close to the 
estimate of the effect on the health outcome 
(level 3, or ⊕⊕⊕). 
Conclusion 
We are moderately confident that the risk of serious 
adverse events following a single dose of Janssen 




1. FDA Briefing Document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. 
(https://www.fda.gov/media/146217/download, accessed 25 February 2021). 
2. Sadoff J, Le GM, Shukarev G, Heerwegh D, Truyers C, de Groot AM et al. Interim results of a phase 1-2a 
trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021; Jan 13. 
  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for the following limitations. The trial was not adequately powered to detect rare adverse events (i.e. fewer than 
about 1 in 2000). These may emerge only when large populations have been vaccinated. The limited follow-up time of the 
clinical trial may not allow detection of adverse events occurring several months after vaccination.  
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Annex 3. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in older adults 
 
Population :  Older adults (≥60 years) 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison: Placebo/active control  
Outcome     : Moderate to severe/critical COVID-19 (PCR-confirmed) 
What is the efficacy of a single dose of Janssen AD26.COV2.S vaccine compared with placebo/active control in preventing 
moderate to severe/critical PCR-confirmed COVID-19 in older adults (≥60 years)? 
    Rating Adjustment to rating 
   











No. of studies/starting rating 






Limitation in study 
designa Not serious 0 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not seriousb 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  













Statement on quality of evidence 
Evidence supports a high level of confidence 
that the true effect lies close to the estimate of 
the effect on the health outcome (level 4, or 
⊕⊕⊕⊕). 
Conclusion 
We are confident that a single dose of JANSSEN 
AD26.COV2.S vaccine is efficacious in preventing 
moderate to severe/critical PCR-confirmed COVID-
19 in older adults (≥60 years). 
 
References 
1. FDA Briefing Document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. 
(https://www.fda.gov/media/146217/download, accessed 25 February 2021). 
2. Sadoff J, Le GM, Shukarev G, Heerwegh D, Truyers C, de Groot AM et al. Interim results of a phase 1-2a 
trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021; Jan 13. 
  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Approximately 40% of the trial participants were aged 60 years or over. Data on long-term protection emerging from the 
ongoing phase 3 clinical trial remain limited, as trial data have so far been reported only for a follow-up of approximately 2 
months. This was considered as not constituting a limitation that would lead to downgrading of the evidence. SAGE will 
continue to review any emerging data and adjust its quality assessment as required. 
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Annex 4. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in older adults 
 
Population :  Older adults (≥60 years) 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison: Placebo/active control  
Outcome     : Serious adverse events following immunization 
What is the risk of serious adverse events following Janssen AD26.COV2.S vaccination compared with placebo/active control 
in older adults (≥60 years)? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Serious
b -1 
Inconsistency Not serious 0 
Indirectness Not serious 0 
Imprecision Not seriousc 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  













Statement on quality of evidence 
Evidence supports a moderate level of 
confidence that the true effect lies close to the 
estimate of the effect on the health outcome 
(level 3, or ⊕⊕⊕). 
Conclusion 
We are moderately confident that the risk of serious 
adverse events following a single dose of Janssen 




1. FDA Briefing Document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. 
(https://www.fda.gov/media/146217/download, accessed 25 February 2021). 
2. Sadoff J, Le GM, Shukarev G, Heerwegh D, Truyers C, de Groot AM et al. Interim results of a phase 1-2a 
trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021; Jan 13.  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for the following limitations. The trial was not adequately powered to detect rare adverse events (i.e. about 1 in 
250). These may emerge only when large populations have been vaccinated. The limited follow-up time of the clinical trial 
may not allow detection of adverse events occurring several months after vaccination. 
c Approximately 40% of the trial participants were aged 60 years or over. This was not considered as constituting a limitation 
that leads to downgrading of the evidence.  
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Annex 5. GRADE table: Efficacy of Janssen AD26.COV2.S COVID-19 vaccine in individuals with 
underlying conditions 
Population :  Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison: Placebo/active control 
Outcome     : Moderate to severe/critical COVID-19 (PCR-confirmed) 
What is the efficacy of a single dose of Janssen AD26.COV2.S vaccine compared with placebo/active control in preventing 
moderate to severe/critical PCR-confirmed COVID-19 in individuals with comorbidities or health states that increase risk for 
severe COVID-19? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Not serious 0 
Inconsistency Not serious 0 
Indirectness Seriousb  -1 
Imprecision Not seriousc 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  












Statement on quality of evidence 
Evidence supports a moderate level of 
confidence that the true effect lies close to the 
estimate of the effect on the health outcome 
(level 3, or ⊕⊕⊕). 
Conclusion 
We are moderately confident that a single dose of 
Janssen AD26.COV2.S vaccine is efficacious in 
preventing moderate to severe/critical PCR-
confirmed COVID-19 in individuals with 
comorbidities or health states that increase risk for 
severe COVID-19, as included in the clinical trial. 
No data were obtained on vaccination of pregnant 




1. FDA Briefing Document. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. 
(https://www.fda.gov/media/146217/download, accessed 25 February 2021). 
2. Sadoff J, Le GM, Shukarev G, Heerwegh D, Truyers C, de Groot AM et al. Interim results of a phase 1-2a 
trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021; Jan 13.  
 
a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Trial excluded pregnant and breastfeeding women, and persons who were immunocompromised. This was considered as 
constituting a limitation that leads to downgrading of the evidence.  
c  Underlying comorbidities included BMI ≥ 30 kg/m2, cardiovascular disorder, respiratory disease and diabetes. 
Approximately 40% of the trial population had at least one comorbidity. This was considered as not constituting a limitation 
that would lead to downgrading of the evidence. Data on long-term protection emerging from the ongoing phase 3 clinical 
trial remain limited, as trial data have so far been reported only for a follow-up of approximately 2 months. This was considered 
as not constituting a limitation that would lead to downgrading of the evidence. SAGE will continue to review any emerging 
data and adjust its quality assessment as required. 
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Annex 6. GRADE table: Safety of Janssen AD26.COV2.S COVID-19 vaccine in individuals with underlying 
conditions 
Population :  Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison: Placebo/active control 
Outcome     : Serious adverse events following immunization 
What is the risk of serious adverse events following Janssen AD26.COV2.S vaccination compared with placebo/active control 
in individuals with comorbidities or health states that increase risk for severe COVID-19? 
    Rating Adjustment to rating 
   















Limitation in study 
designa Serious
b -1 
Inconsistency Not serious 0 
Indirectness Seriousc -1 
Imprecision Not serious 0 




Large effect Not applicable  0 
Dose-response Not applicable  0  
Antagonistic bias 
and confounding Not applicable  0  












Statement on quality of evidence 
Evidence supports a limited level of confidence 
that the true effect lies close to the estimate of 
the effect on the health outcome (level 2, or 
⊕⊕). 
Conclusion 
We have low confidence in the quality of evidence 
that the risk of serious adverse events in individuals 
with comorbidities or health states that increase risk 
for severe COVID-19 following a single dose of 
Janssen AD26.COV2.S vaccine is low. 
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a For the risk of bias assessments using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2), please see 
www.covid-nma.com/vaccines. 
b Downgraded for the following limitations. The trial was not adequately powered to detect rare adverse events (i.e. fewer than 
about 1 in 800). These may emerge only when large populations have been vaccinated. The limited follow-up time of the 
clinical trial may not allow detection of adverse events occurring several months after vaccination. 
c Trial excluded pregnant and breastfeeding women and persons who were immunocompromised. This was considered as 
constituting a limitation that leads to downgrading of the evidence.  
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Annex 7. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in adults 
Question: Should Janssen AD26.COV2.S vaccine be administered to adults to prevent moderate to severe/critical  COVID-19?  
Population:  Adults (18–59 years) 
Intervention:  Single dose of JANSSEN AD26.COV2.S vaccine 
Comparison(s):  Active control/placebo 
Outcome:   Moderate to severe/critical COVID-19 (PCR-confirmed) 
Background:  On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was 
found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a 
public health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-being of individuals 
and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
Vaccines are a critical tool in combating the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has to date issued interim recommendations on the 
use of Pfizer–BioNTech, Moderna and AstraZeneca vaccines (3-5). 
 
 
















The cumulative number of COVID-19 cases 
globally has surpassed 111 762 965 with more 
than 2 479 678 deaths. Cases have been found 
in 190 different countries or territories throughout 
the world (status 25 February 2021). There has 
been collateral damage to other public health 
programmes. 
 
The COVID-19 situation is evolving 
rapidly; the most recent 
epidemiological situation can be 





☐ ☐ ☒ ☐ 























Benefits of the 
intervention 
 





No Un-certain Yes 
Varie
s 
The phase 3 study COV3001 demonstrated 
63.7%  efficacy (95%CI 53.9–71.6%) in people 
aged 18–59 years against confirmed moderate to 
severe/critical COVID-19 from 14 days after 
vaccination. 
 
In all participants, as from 14 days after 
vaccination, 2 COVID-19-related hospitalizations 
were observed in the vaccinated group compared 






☐ ☐ ☒ ☐ 






effects small?  
No Un-certain Yes 
Varie
s  
Ad26.COV2.S demonstrated an acceptable 
safety and reactogenicity profile in adults ≥18 
years of age and in adults ≥60 years of age, 
including those with comorbidities associated 
with an increased risk of progressing to 
severe/critical COVID-19. 
 
All local and systemic adverse reactions were 
reported more frequently among younger (18–59 
years) than among older (≥60 years) participants. 
 
In those aged 18–59 years, 4/14 564 (<0.1%)  in 
the vaccine group reported related serious 
adverse events compared with 1/14 547 (<0.1%) 
in the placebo group. 
 
























Efficacy data suggest benefit, and short-term 
safety data suggest minimal harms. Further 
ongoing studies will need to be undertaken as 
part of post-marketing surveillance. 
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☒ ☐ ☐ ☐ ☐ 
What is the 
overall quality of 
this evidence for 
the critical 
outcomes? 



















Low Mod-erate High 
☐ ☐ ☐ ☐ ☒ 
 
 








Low Mod-erate High 































































Available scientific evidence on the relative 
importance of the intervention, as well as the 
relative weights that the target population 
attributes to the desirable (i.e. protection 
conferred by the vaccine) and the undesirable 
outcomes (i.e. the currently reported safety 
signals), varies.  
 
Different population groups may have different 
opinions regarding the weights assigned to 
desirable and undesirable outcomes.  
 
 






















Available scientific evidence suggests that the 
target population probably assigns more weight 
to the desirable effects than to the undesirable 
effects related to COVID-19 vaccination. 
 







☐ ☐ ☐ ☒ ☐ ☐ 



















s  Janssen AD26.COV2.S vaccine can be distributed and stored using existing cold-chain 
infrastructure and does not require ultra-cold-
chain capacity. Nevertheless, considerable 
resources will be needed to ensure the 
implementation of a COVID-19 vaccination 
programme, especially given: (i) that COVID-19 
vaccination is likely to be prioritized for 
populations (e.g. health care workers, older 
adults) without pre-existing robust immunization 
programmes in many settings, and (ii) the 
urgency of vaccination roll-out worldwide, which 
may necessitate additional surge resources to 
accelerate implementation with adequate 
infection prevention and control procedures in the 
context of COVID-19. Resources required 
include, but are not restricted to, human 
resources, vaccine costs, logistics, planning and 
coordination, training, social mobilization and 
communications, and immunization safety 
surveillance.  
An estimated US$15.9 billion is 
needed for the vaccines pillar 
(COVAX) of the Access to COVID-19 
Tools Accelerator (ACT-A) for 2020–
21, in order to deliver 2 billion doses. 
This does not include all delivery 
costs in all countries participating in 
COVAX, bilateral procurement deals, 
or research and development 
investments outside of COVAX (6). 
The World Bank has approved a 
financing window of up to US$12 
billion to support low- and middle-
income countries in purchasing and 
distributing vaccine (7). 









Formal global cost-effectiveness analyses have 
not been conducted, but the emerging evidence 
indicates that the benefits, including the impact 
on recovery of the global economy, are likely to 
outweigh the cost of COVID-19 vaccination in 
general at global level.  
 
No formal cost-effectiveness analyses of Janssen 
AD26.COV2.S vaccine compared with other 
vaccines have been conducted. The Janssen 
AD26.COV2.S vaccine is expected to be less 
costly than other COVID-19 vaccines (see 
previous subcriterion).(8) Individual-level efficacy 
against COVID-19 may be lower than that of 
The global economy is estimated to 
be losing US$375 billion per month 
because of the coronavirus 
pandemic. G20 countries have 
invested approximately US$10 trillion 
in domestic economic stimulus to 
mitigate the economic consequences 
of reduced business activity and 
unemployment due to the pandemic. 
Initial estimates suggest that COVID-
19 vaccination will provide 
substantial economic value in terms 
of averted morbidity and mortality 
costs and averted losses in gross 
domestic product (GDP) (6;9-15). 
☐ ☐ ☐ ☒ 
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some other COVID-19 vaccines; more data are 
needed to assess efficacy against other 
endpoints (see main text). The ability to use 
Janssen AD26.COV2.S in existing cold-chain 
infrastructure in all country settings may allow 
higher population-level coverage.  
 
Cost-effectiveness analyses should be 
conducted at country level; cost-effectiveness of 
COVID-19 vaccination may vary by country 
depending on COVID-19 burden, comparator 
interventions assessed, analysis perspective, 





What would be 









Equity and ethical considerations are critical. 
SAGE has produced a Values Framework (16), 
which offers guidance on the fair allocation of 
COVID-19 vaccines based on six core ethical 
principles that should guide distribution. If 
distributed fairly, COVID-19 vaccines may have 
considerable impact on reducing health 
inequities.   
 
Storage and distribution requirements of the 
Janssen AD26.COV2.S vaccine are the same as 
those of many other vaccines currently in use 
globally. Existing vaccine cold-chain capacity, 
available in almost all countries, could be 
leveraged for vaccine distribution. 
Vaccine nationalism is seen as a 
threat to reducing health inequity, in 
particular as high-income countries 
have arranged bilateral contracts 
with manufacturers. This has led to 
the establishment of the  Access to 
COVID-19 Tools (ACT) Accelerator 
and, within this, the COVAX facility, 
which aims to ensure equitable 
access to vaccines for its 
participating member states (17). 



























No scientific evidence is available. As vaccination 
is an eagerly awaited tool to combat COVID-19, it 
is assumed that key stakeholders, in particular 
ministries of health and immunization managers, 
are strongly in favour of it. 
 
The fact that 190 economies are 
participating in COVAX suggests a 
very high acceptability of COVID-19 
vaccination in general, though not 
necessarily of this vaccine in 
particular. 
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☒ ☐ ☐ ☐ ☐ 













Single-dose administration of this product may be 
favourable to the target group. 
 
COVID-19 vaccine acceptability in general varies 
between (sub)population groups and may be 
correlated with the perceived risk posed by the 
disease. In a global survey (19 countries) of 
acceptance rates in the general population of any 
COVID-19 vaccine product, 71.5% of participants 
reported that they would be very or somewhat 
likely to take a COVID-19 vaccine. Acceptance 
rates ranged from almost 55% to 87% (18). 
 
Representative multicountry surveys are carried 
out periodically to assess the percentage of those 
willing to receive (or of those who have already 
received) COVID-19 vaccination (non-product-
specific). While these polls are limited to selected 
countries, they  provide a certain degree of insight 


































Single-dose administration of this vaccine is 
assumed to be easily implementable in settings – 
including low- and middle-income-countries – 
with existing vaccine logistics and delivery 
infrastructure. 
 
Ad26.COV2.S can be stored for at least 3 months 
at normal refrigerator temperatures of 2°C to 8°C 
(36°F to 46°F), and its shipping and storage fit 
 
☐ ☐ ☐ ☐ ☒ ☐ 
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 into the existing medical supply infrastructure (21). 
 
Administration of the vaccine to target groups that 
are currently not reached by national 
immunization programmes may pose a challenge 






clearly outweigh  
desirable 
consequences 
in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or uncertain 
 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 
☐ ☐ ☐ ☐ ☒ 
Type of recommendation 
We recommend 
the intervention 
We suggest considering recommendation of the 
intervention 
We recommend the 
comparison 
We recommend against 
the intervention and the 
comparison 




☒ Only with targeted monitoring and evaluation 
☐ Only in specific contexts or specific (sub)populations 
Recommendation (text) 
Ad26.COV2.S is recommended for use in persons aged 18 years and above. The recommended schedule is one dose (0.5 ml) given 
intramuscularly into the deltoid muscle. 



















and research priorities 
WHO recommends the following post-authorization monitoring activities and research. 
 
• Safety surveillance and monitoring: 
− anaphylaxis, thromboembolic events and other serious adverse events, cases of COVID-19 following vaccination 
that result in hospitalization or death; 
− background rates of AESIs, maternal and neonatal outcomes, and mortality in groups prioritized for vaccination. 
• Vaccine effectiveness: 
− vaccine effectiveness in relation to new virus variants; 
− vaccine effectiveness over time and whether protection can be prolonged by booster doses; 
− booster studies with a second dose, heterologous or variant-adjusted vaccines; 
− studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
− assessment and reporting of breakthrough infections and virus sequence information; 
− head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization, T-
cell and mucosal immunity assays; 
− vaccine effectiveness against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), chronic COVID syndrome 
(CCS) and long-haul COVID. 
• Subpopulations: 
− prospective studies on the safety of Ad26.COV2.S vaccine in pregnant and lactating women; 
− immunogenicity and safety of vaccination in persons below the age of 18 years; 
− safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with 
autoimmune disease. 
• Vaccination logistics: 
− immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
− interchangeability and “mix and match” studies for boosters within and across COVID-19 vaccine platforms. 
• Virus variants: 
− global surveillance of virus evolution and the impact of virus variants on vaccine effectiveness to support update of 
vaccines; 
− modelling to determine the trade-offs for the use of vaccines with reduced effectiveness against emergent variants; 
− booster studies with updated vaccine formulations. 
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Annex 8. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in older adults 
 
Question: Should Janssen AD26.COV2.S vaccine be administered to older adults to prevent moderate to severe/critical COVID-19?  
Population: Older adults (≥60 years) 
Intervention: Single dose of Janssen AD26.COV2.S vaccine 
Comparison(s):  Active control/placebo 
Outcome:  Moderate to severe/critical COVID-19 (PCR-confirmed) 
Background: On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was 
found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a 
public health emergency of international concern in January 2020. The disease has since spread with an enormous impact on the health and well-being of individuals 
and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
Vaccines are a critical tool in combating the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has to date issued interim recommendations on the 
use of Pfizer–BioNTech, Moderna and AstraZeneca vaccines (3-5). 
 
















The cumulative number of COVID-19 cases 
globally has surpassed 111 762 965 with more 
than 2 479 678 deaths. Cases have been found 
in 190 different countries or territories throughout 
the world (status 25 February 2021). There has 
been collateral damage to other public health 
programmes. 
Older adults are particularly affected by COVID-
19 and bear a significantly higher risk of severe 
COVID-19 outcomes and death. 
The COVID-19 situation is evolving 
rapidly; the most recent 
epidemiological situation can be 
found on the following website: 
https://covid19.who.int/table 
 
☐ ☐ ☒ ☐ 























Benefits of the 
intervention 
 





No Un-certain Yes 
Varie
s 
Around 40% of the study population in the 
primary analysis were aged 60 years or older. 
 
The phase 3 study COV3001 demonstrated 
76.3% efficacy (95%CI 61.1–86.0%) in those 
aged 60 years and above against confirmed 
moderate to severe/critical COVID-19 as from 14 
days after vaccination. 
 
In all participants, as of 14 days after vaccination, 
there were 2 COVID-19-related hospitalizations 
in the vaccinated group compared with 29 in the 
placebo group (VE 93.1%, 95%CI 72.74–99.20). 
 
☐ ☐ ☒ ☐ 






effects small?  
No Un-certain Yes 
Varie
s  
Ad26.COV2.S demonstrated an acceptable 
safety and reactogenicity profile in adults ≥18 
years of age, and adults ≥60 years of age, 
including those with comorbidities associated 
with an increased risk of progressing to 
severe/critical COVID-19. 
All local and systemic adverse reactions were 
reported more frequently among younger (18–59 
years) than among older (≥60 years) participants. 
In those aged 60 years and over, 3/7331 (<0.1%) 
in the vaccine group reported related serious 
adverse events compared with 1/7341 (<0.1%) in 
the placebo group. 
  
























Efficacy data benefit of the intervention, and 
short-term safety data suggest limited harm. 
Further ongoing studies will need to be 
undertaken as part of post-marketing 
surveillance. 
 
☒ ☐ ☐ ☐ ☐ 
Effectiveness of the intervention Please see the related GRADE tables.  
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What is the 
overall quality of 










Low Mod-erate High 
☐ ☐ ☐ ☐ ☒ 
 
 








Low Mod-erate High 































































The majority of severe disease occurs in older 
individuals. Available scientific evidence 
suggests that the target population probably 
considers the desirable effects, i.e. the potential 
protection conferred by the vaccine, more 
important than the undesirable effects, i.e. the 
currently reported safety signals related to 
COVID-19 vaccination. 
Different population groups may have different 
opinions regarding the weights assigned to 

































Available scientific evidence suggests that the 
target population probably assigns more weight 
to the desirable effects than the undesirable 
effects related to COVID-19 vaccination. 
 






effects? ☐ ☐ ☐ ☒ ☐ ☐ 
Targeted information campaigns should assess 
this aspect.  
As more data on vaccine efficacy in older adults 
are generated, the uncertainty around the 
importance of the desirable effects of the 




















Janssen AD26.COV2.S can be distributed and 
stored using existing cold-chain infrastructure 
and does not require ultra-cold-chain capacity. 
Nevertheless, considerable resources will be 
needed to ensure the implementation of a 
COVID-19 vaccination programme, especially 
given: (i) that COVID-19 vaccination is likely to be 
prioritized for populations (e.g. health care 
workers, older adults) without pre-existing robust 
immunization programmes in many settings, and 
(ii) the urgency of vaccination roll-out worldwide, 
which may necessitate additional surge 
resources to accelerate implementation with 
adequate infection prevention and control 
procedures in the context of COVID-19. 
Resources required include, but are not restricted 
to, human resources, vaccine costs, logistics, 
planning and coordination, training, social 
mobilization and communications, and 
immunization safety surveillance.  
An estimated US$15.9 billion is 
needed for the vaccines pillar 
(COVAX) of the Access to COVID-19 
Tools Accelerator (ACT-A) for 2020–
21, in order to deliver 2 billion doses. 
This does not include all delivery 
costs in all countries participating in 
COVAX, bilateral procurement deals, 
or research and development 
investments outside of COVAX (6). 
 
The World Bank has approved a 
financing window of up to US $12 
billion to support low- and middle-
income countries in purchasing and 
distributing vaccine (7). 









Formal global cost-effectiveness analyses have 
not been conducted, but the emerging evidence 
indicates that the benefits, including the impact 
on recovery of the global economy, are likely to 
outweigh the cost of COVID-19 vaccination in 
general at global level.  
No formal cost-effectiveness analyses of Janssen 
AD26.COV2.S vaccine compared with other 
vaccines have been conducted. The Janssen 
AD26.COV2.S vaccine is expected to be less 
costly than  
 other COVID-19 vaccines (see previous 
subcriterion). (8) Individual-level efficacy against 
The global economy is estimated to 
be losing US$375 billion per month 
because of the coronavirus 
pandemic. G20 countries have 
invested approximately US$10 trillion 
in domestic economic stimulus to 
mitigate the economic consequences 
of reduced business activity and 
unemployment due to the pandemic. 
Initial estimates suggest that COVID-
19 vaccination will provide 
substantial economic value in terms 
of averted morbidity and mortality 
☐ ☐ ☐ ☒ 
Background document on the Janssen Ad26.COV2.S (COVID-19) vaccine 
 
-39- 
COVID-19 may be lower than that of some other 
COVID-19 vaccines; more data are needed to 
assess efficacy against other endpoints (see 
main text). The ability to use Janssen 
AD26.COV2.S in existing cold-chain 
infrastructure in all country settings may allow 
higher population-level coverage.  
Cost-effectiveness analyses should be 
conducted at country level; cost-effectiveness of 
COVID-19 vaccination may vary by country 
depending on COVID-19 burden, comparator 
interventions assessed, analysis perspective, 
and local cost-effectiveness thresholds used. 
costs and averted losses in gross 





What would be 









Equity and ethical considerations are critical. 
SAGE has produced a Values Framework (16), 
which offers guidance on the fair allocation of 
COVID-19 vaccines based on six core ethical 
principles that should guide distribution. If 
distributed fairly, COVID-19 vaccines may have 
considerable impact on reducing health 
inequities.  
Storage and distribution requirements of Janssen 
AD26.COV2.S vaccine are the same as those of 
many other vaccines currently in use globally. 
Existing vaccine cold-chain capacity, which is 
available in almost all countries, could be 
leveraged for vaccine distribution. 
Vaccine nationalism is seen as a 
threat to reducing health inequity, in 
particular as high-income countries 
have arranged bilateral contracts 
with manufacturers. This has led to 
the establishment of the Access to 
COVID-19 Tools (ACT) Accelerator 
and, within this, the COVAX facility, 
which aims to ensure equitable 
access to vaccines for its 
participating member states (17). 



























No scientific evidence is available. As vaccination 
is an eagerly awaited tool to combat COVID-19, it 
is assumed that key stakeholders, in particular 
ministries of health and immunization managers, 
are strongly in favour of COVID-19 vaccination. 
 
The fact that 190 economies are 
participating in COVAX suggests a 
very high acceptability of COVID-19 
vaccination in general, though not 
necessarily of this vaccine in 
particular.  
☒ ☐ ☐ ☐ ☐ 
Background document on the Janssen Ad26.COV2.S (COVID-19) vaccine 
 
-40- 













Single-dose administration of this product may be 
favourable to the target group. 
COVID-19 vaccine acceptability varies between 
(sub)population groups and may be correlated 
with the perceived risk posed by the disease. In a 
global survey (19 countries) of acceptance rates 
in the general population of any COVID-19 
vaccine product, 71.5% of participants reported 
that they would be very or somewhat likely to take 
a COVID-19 vaccine. Acceptance rates ranged 
from almost 55% to 87% (18). 
Representative multicountry surveys are carried 
out periodically to assess the percentage of those 
willing to receive (or of those who have already 
received) COVID-19 vaccination (non-product 
specific). While these polls are limited to selected 
countries, they provide a certain degree of insight 
into vaccine acceptance and trends over time 
(19;20) 
 































Single-dose administration of this vaccine is 
assumed to be easily implementable in settings – 
including low- and middle-income-countries – 
with existing vaccine logistics and delivery 
infrastructure. 
Ad26.COV2.S can be stored for at least 3 months 
at normal refrigerator temperatures of 2°C to 8°C 
(36°F to 46°F), and its shipping and storage fit 
into the existing medical supply infrastructure (21) 
 





clearly outweigh  
desirable 
consequences 
in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or uncertain 
 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 
☐ ☐ ☐ ☐ ☒ 
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Type of recommendation 
We recommend 
the intervention 
We suggest considering recommendation of the 
intervention 
 
We recommend the 
comparison 
We recommend against 
the intervention 
and the comparison 
 




☒ Only with targeted monitoring and evaluation 
☐ Only in specific contexts or specific (sub)populations 
Recommendation (text) 
The risk of severe COVID-19 and death increases steeply with age. Data from the phase 3 trial indicate that the efficacy and safety of 






WHO recommends the following post-authorization monitoring activities and research. 
 
• Safety surveillance and monitoring: 
− anaphylaxis, thromboembolic events and other serious adverse events, cases of COVID-19 following vaccination 
that result in hospitalization or death; 
− background rates of AESIs, maternal and neonatal outcomes, and mortality in groups prioritized for vaccination. 
• Vaccine effectiveness: 
− vaccine effectiveness in relation to new virus variants; 
− vaccine effectiveness over time and whether protection can be prolonged by booster doses; 
− booster studies with a second dose, heterologous or variant-adjusted vaccines; 
− studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
− assessment and reporting of breakthrough infections and virus sequence information; 
− head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization, T-
cell and mucosal immunity assays; 
− vaccine effectiveness against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), chronic COVID syndrome 
(CCS) and long-haul COVID. 
• Subpopulations: 
− prospective studies on the safety of Ad26.COV2.S vaccine in pregnant and lactating women; 
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Europe. (www.rand.org/t/RRA769-1, accessed 13 December 2020).  
− immunogenicity and safety of vaccination in persons below the age of 18 years; 
− safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with 
autoimmune disease. 
• Vaccination logistics: 
− immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
− interchangeability and “mix and match” studies for boosters within and across COVID-19 vaccine platforms. 
• Virus variants: 
− global surveillance of virus evolution and the impact of virus variants on vaccine effectiveness to support update of 
vaccines; 
− modelling to determine the trade-offs for the use of vaccines with reduced effectiveness against emergent variants; 
− booster studies with updated vaccine formulations.  
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Annex 9. SAGE evidence-to-recommendation framework: Janssen AD26.COV2.S vaccine use in individuals with comorbidities 
 
 
a Comorbidity in the phase 3 trial was defined as asthma, cancer, chronic kidney disease, cardiovascular disorder, respiratory disease, obesity, neurological conditions, immunocompromised from 
blood transplant, HIV infection or diabetes type 2. 
Question: Should Janssen AD26.COV2.S vaccine be administered to individuals with comorbidities or health states that increase risk for severe COVID-19a to 
prevent moderate to severe/critical COVID-19?  
Population:  Individuals with comorbidities or health states that increase risk for severe COVID-19 
Intervention: Single dose of JANSSEN AD26.COV2.S vaccine 
Comparison(s): Active control/placebo 
Outcome: Moderate to severe/critical COVID-19 (PCR-confirmed) 
Background: On 31 December 2019, WHO was alerted to several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. The cause was 
found to be a novel coronavirus, SARS-CoV-2. The disease caused by this novel virus has been named COVID-19. The outbreak of COVID-19 was declared a 
public health emergency of international concern in January 2020. The disease has since spread, with an enormous impact on the health and well-being of individuals 
and populations worldwide. It has further caused major disruptions to various sectors of society and the economy across the globe. 
Vaccines are a critical tool in combating the pandemic. In the rapidly evolving field of COVID-19 vaccines, WHO has to date issued interim recommendations on the 
use of Pfizer–BioNTech, Moderna and AstraZeneca vaccines (3-5). 
















The cumulative number of COVID-19 cases 
globally has surpassed 111 762 965 with more 
than 2 479 678 deaths. Cases have been found 
in 190 different countries or territories throughout 
the world (status 25 February 2021). There has 
been collateral damage to other public health 
programmes. 
Individuals with certain comorbidities are 
particularly affected by COVID-19 and bear a 
higher risk of severe COVID-19 outcomes and 
death. Identified risk factors include comorbidities 
such as diabetes, hypertension, cardiac disease, 
chronic lung disease, cerebrovascular disease, 
dementia, mental disorders, chronic kidney 
The COVID-19 situation is evolving 
rapidly; the most recent 
epidemiological situation can be 





☐ ☐ ☒ ☐ 
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disease, immunosuppression, obesity and 
cancer. People with multiple comorbidities are at 
a higher risk of COVID-19-related adverse 
outcomes (22) Although the relative risk may be 
high for some conditions, the absolute risk for 
younger adults with comorbidities is typically 





















Benefits of the 
intervention 
 




No Un-certain Yes 
Varie
s 
At least one comorbidity was present for 39.9% of 
participants. 
The phase 3 study COV3001 demonstrated 
64.2% efficacy (95%CI 52.7–73.1) in those with 
comorbidities  
against confirmed moderate to severe/critical 
COVID-19 as from 14 days after vaccination. 
 
☐ ☐ ☒ ☐ 






effects small?  
No Un-certain Yes 
Varie
s  
Ad26.COV2.S demonstrated an acceptable 
safety and reactogenicity profile in adults ≥18 
years of age, and adults ≥60 years of age, 
including those with comorbidities associated 
with an increased risk of progressing to 
severe/critical COVID-19. 
 
   
























Efficacy data suggest benefit, and the short-term 
safety data suggest minimal harm. Further 
studies will need to be undertaken as part of post-
marketing surveillance. 
 
☒ ☐ ☐ ☐ ☐ 
What is the 
overall quality of 
this evidence for 
the critical 
outcomes? 








Low Mod-erate High 
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☐ ☐ ☐ ☒ ☐ 
 








Low Mod-erate High 































































There is possibly important uncertainty regarding 
how the target population weighs the desirable 
and undesirable effects (i.e. the protection 
conferred by the vaccine weighed against the 
currently reported safety signals) related to 
COVID-19 vaccination. 
Different population groups may have different 
opinions regarding the relative weights attributed 
to desirable and undesirable outcomes. 
 


























It is assumed that target population probably 
attaches more weight to the desirable effects than 
the undesirable effects related to COVID-19 
vaccination. 
Targeted information campaigns should assess 
this aspect. 
 








s  Janssen AD26.COV2.S can be distributed and stored using existing cold-chain infrastructure 
An estimated US$15.9 billion is 
needed for the vaccines pillar 






☒ ☐ ☐ ☐ 
and does not require ultra-cold-chain capacity. 
Nevertheless, considerable resources will be 
needed to ensure the implementation of a 
COVID-19 vaccination programme, especially 
given: (i) that COVID-19 vaccination is likely to be 
prioritized for populations (e.g. health care 
workers, older adults) without pre-existing robust 
immunization programmes in many settings, and 
(ii) the urgency of vaccination roll-out worldwide, 
which may necessitate additional surge 
resources to accelerate implementation with 
adequate infection prevention and control 
procedures in the context of COVID-19. 
Resources required include, but are not restricted 
to, human resources, vaccine costs, logistics, 
planning and coordination, training, social 
mobilization and communications, and 
immunization safety surveillance.  
(COVAX) of the Access to COVID-19 
Tools Accelerator (ACT-A) for 2020–
21, in order to deliver 2 billion vaccine 
doses. This does not include all 
delivery costs in all countries 
participating in COVAX, bilateral 
procurement deals, or research and 
development investments outside of 
COVAX (6). 
 
The World Bank has approved a 
financing window of up to US$12 
billion to support low- and middle-
income countries in purchasing and 






s Formal global cost-effectiveness analyses have not been conducted, but the emerging evidence 
indicates that the benefits, including the impact 
on recovery of the global economy, are likely to 
outweigh the cost of COVID-19 vaccination in 
general at global level.  
No formal cost-effectiveness analyses of Janssen 
AD26.COV2.S compared with other vaccines 
have been conducted. The Janssen 
AD26.COV2.S vaccine is expected to be less 
costly than other COVID-19 vaccines (see 
previous subcriterion). (8)Individual-level efficacy 
against COVID-19 may be lower than for some 
other COVID-19 vaccines; more data are needed 
to assess efficacy against other endpoints (see 
main text). The ability to use Janssen 
AD26.COV2.S in existing cold-chain 
infrastructure in all country settings may allow 
higher population-level coverage.  
Cost-effectiveness analyses should be 
conducted at country level; cost-effectiveness of 
COVID-19 vaccination may vary by country 
depending on COVID-19 burden, comparator 
The global economy is estimated to 
be losing US$375 billion per month 
because of the coronavirus 
pandemic. G20 countries have 
invested approximately US$10 trillion 
in domestic economic stimulus to 
mitigate the economic consequences 
of reduced business activity and 
unemployment due to the pandemic. 
Initial estimates suggest that COVID-
19 vaccination will provide 
substantial economic value in terms 
of averted morbidity and mortality 
costs and averted losses in gross 
domestic product (GDP) (6;9-15). 
 
☐ ☐ ☐ ☒ 
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interventions assessed, analysis perspective, 





What would be 









Equity and ethical considerations are critical. 
SAGE has produced a Values Framework (16), 
which offers guidance on the fair allocation of 
COVID-19 vaccines based on six core ethical 
principles that should guide distribution. If 
distributed fairly, COVID-19 vaccines may have 
considerable impact on reducing health 
inequities.  
Storage and distribution requirements of Janssen 
AD26.COV2.S vaccine are the same as for many 
other vaccines currently in use globally. Existing 
vaccine cold-chain capacity, available in almost 
all countries worldwide, could be leveraged for 
vaccine distribution. 
Vaccine nationalism is seen as a 
threat to reducing health inequity, in 
particular as high-income countries 
have arranged bilateral contracts 
with manufacturers. This has led to 
the establishment of the Access to 
COVID-19 Tools (ACT) Accelerator 
and, within this, the COVAX facility, 
which aims to ensure equitable 
access to vaccines for its 
participating member states (17). 



























No scientific evidence is available. As vaccination 
is an eagerly awaited tool to combat COVID-19, it 
is assumed that key stakeholders, in particular 
ministries of health and immunization managers, 
are strongly in favour of COVID-19 vaccination. 
The fact that 190 economies are 
participating in COVAX suggests a 
very high acceptability of COVID-19 
vaccination in general, though not 
necessarily of this vaccine in 
particular.  
☒ ☐ ☐ ☐ ☐ 












Single-dose administration of this product may be 
favourable to the target group. 
COVID-19 vaccine acceptability in general varies 
between (sub)population groups and may be 
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☒ ☐ ☐ ☐ ☐ 
correlated with the perceived risk posed by the 
disease. In a global survey (19 countries) of 
acceptance rates in the general population of any 
COVID-19 vaccine product, 71.5% of participants 
reported that they would be very or somewhat 
likely to take a COVID-19 vaccine. Acceptance 
rates ranged from almost 55% to 87% (18). 
 
Representative multicountry surveys are carried 
out periodically to assess the percentage of those 
willing to receive (or of those who have already 
received) COVID-19 vaccination (non-product 
specific). While these polls are limited to selected 
countries, they provide a certain degree of insight 






























Single-dose administration of this vaccine is 
assumed to be easily implementable in settings – 
including low- and middle-income countries – with 
existing vaccine logistics and delivery 
infrastructure. 
Ad26.COV2.S can be stored for at least 3 months 
at normal refrigerator temperatures of 2°C to 8°C 
(36°F to 46°F), and its shipping and storage fit 
into the existing medical supply infrastructure 
(21). 
 





clearly outweigh  
desirable 
consequences 
in most settings 
Undesirable 
consequences 
probably outweigh  
desirable 
consequences 
in most settings 
 
The balance between  
desirable and undesirable 
consequences  
is closely balanced or uncertain 
 
Desirable consequences  
probably outweigh  
undesirable 
consequences 
in most settings 
 
Desirable consequences  
clearly outweigh  
undesirable 
consequences 
in most settings 
☐ ☐ ☐ ☒ ☐ 
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Type of recommendation 
We recommend 
the intervention 
We suggest considering recommendation of the 
intervention 
 
We recommend the 
comparison 
We recommend against 
the intervention 
and the comparison 
 




☒ Only with targeted monitoring and evaluation 
☒ Only in specific contexts or specific (sub)populations 
Recommendation (text) 
Persons with comorbidities 
Certain comorbidities have been identified as increasing the risk of severe COVID-19 disease and death. The phase 3 clinical trial 
demonstrated that the vaccine has similar safety and efficacy profiles in persons with various underlying medical conditions, including 
those that place them at increased risk for severe COVID-19. The comorbidities studied in the phase 3 clinical trial included 
hypertension, chronic lung disease, significant cardiac disease, obesity, diabetes, and human immunodeficiency virus (HIV) infection. 
Vaccination is recommended for persons with such comorbidities that have been identified as increasing the risk of severe COVID-19. 
Pregnant women 
Pregnant women are at higher risk of severe COVID-19 compared with women of childbearing age who are not pregnant, and COVID-
19 has been associated with an increased risk of preterm birth. The available data on Ad26.COV2.S of pregnant women are insufficient 
to assess vaccine-associated risks in pregnancy. However, it should be noted that Ad26.COV2.S is a nonreplicating vaccine. No safety 
issues in more than 1 600 pregnant women were identified using the Ad26 vaccine platform for other pathognes including Ebola virus.  
Animal developmental and reproductive toxicity studies show no harm to the development of the foetus. Further studies are planned 
in pregnant women in the coming months, including a pregnancy sub-study and a pregnancy registry. As data from these studies 
become available, recommendations on vaccination will be updated accordingly. In the interim, pregnant women should receive 
Ad26.COV2.S only if the benefit of vaccination to the pregnant woman outweighs the potential vaccine risks, such as if they are health 
workers at high risk of exposure or have comorbidities that place them in a high-risk group for severe COVID-19. Information and, if 
possible, counselling on the lack of safety data for pregnant women and the potential benefit of vaccination should be provided.  
WHO does not recommend pregnancy testing prior to vaccination. WHO does not recommend delaying pregnancy because of 
vaccination.  
Lactating women 
Breastfeeding offers substantial health benefits to lactating women and their breastfed children. Vaccine efficacy is expected to be 
similar in lactating women as in other adults. It is unknown whether Ad26.COV2.S is excreted in human milk. As the Ad26.COV2.S 
vaccine is a nonreplicating vaccine, it is unlikely to pose a risk to the breastfeeding child. On the basis of these considerations, a 
lactating woman who is part of a group recommended for vaccination, e.g., health workers, should be offered vaccination on an 
equivalent basis. WHO does not recommend discontinuing breastfeeding after vaccination.  




Persons living with HIV 
Persons living with human immunodeficiency virus (HIV) may be at higher risk of severe COVID-19. Persons living with HIV who were 
well controlled were included in the trials and no safety concern was observed. Data on administration of the vaccine are currently 
insufficient to allow assessment of vaccine efficacy for persons living with HIV. It is possible that the immune response to the vaccine 
may be reduced, which may lower its clinical effectiveness. In the interim, given that the vaccine is nonreplicating, persons living with 
HIV who are part of a group recommended for vaccination may be vaccinated. Information and, where possible, counselling should be 
provided to inform individual benefit–risk assessment. It is not necessary to test for HIV infection prior to vaccine administration.  
Immunocompromised persons  
Immunocompromised persons are at higher risk of severe COVID-19. Available data are currently insufficient to assess vaccine efficacy 
or vaccine-associated risks in severely immunocompromised persons, including those receiving immunosuppressant therapy. It is 
possible that the immune response to the vaccine may be reduced, which may lower its clinical effectiveness. In the interim, given that 
the vaccine is nonreplicating, immunocompromised persons who are part of a group recommended for vaccination may be vaccinated. 
Information and, where possible, counselling about vaccine safety and efficacy profiles in immunocompromised persons should be 







WHO recommends the following post-authorization monitoring activities and research. 
 
• Safety surveillance and monitoring: 
− anaphylaxis, thromboembolic events and other serious adverse events, cases of COVID-19 following vaccination 
that result in hospitalization or death; 
− background rates of AESIs, maternal and neonatal outcomes, and mortality in groups prioritized for vaccination. 
• Vaccine effectiveness: 
− vaccine effectiveness in relation to new virus variants; 
− vaccine effectiveness over time and whether protection can be prolonged by booster doses; 
− booster studies with a second dose, heterologous or variant-adjusted vaccines; 
− studies to investigate whether this vaccine reduces SARS-CoV-2 transmission and viral shedding; 
− assessment and reporting of breakthrough infections and virus sequence information; 
− head-to-head studies with other vaccines on extent and duration of immunity using standardized neutralization, T-
cell and mucosal immunity assays; 





− vaccine effectiveness against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), chronic COVID syndrome 
(CCS) and long-haul COVID. 
• Subpopulations: 
− prospective studies on the safety of Ad26.COV2.S vaccine in pregnant and lactating women; 
− immunogenicity and safety of vaccination in persons below the age of 18 years; 
− safety data on vaccination in immunocompromised persons, including persons living with HIV and persons with 
autoimmune disease. 
• Vaccination logistics: 
− immunogenicity and safety studies of co-administration with other vaccines, including influenza and pneumococcal 
vaccines, to adults and older persons; 
− safety, immunogenicity, and impact of a delayed second dose, as currently implemented by certain countries; 
− interchangeability and “mix and match” studies for boosters within and across COVID-19 vaccine platforms. 
• Virus variants: 
− global surveillance of virus evolution and the impact of virus variants on vaccine effectiveness to support update of 
vaccines; 
− modelling to determine the trade-offs for the use of vaccines with reduced effectiveness against emergent variants; 
− booster studies with updated vaccine formulations.  
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